Zacks Investment Research downgraded shares of SAREPTA THERAP (SRPT) from OUTPERFORM to NEUTRAL on August 13, 2012, with a target price of $10.20.
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy. Sarepta Therapeutics, Inc., formerly known as AVI BioPharma, Inc., is headquartered in Bothell, Washington.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on SAREPTA THERAP (SRPT),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment